Inhibrx Biosciences (INBX) Receivables (2023 - 2025)
Inhibrx Biosciences' (INBX) quarterly Receivables came in at -$706000.0 in Q4 2025, down 1338.6% year-on-year from $57000.0 in Q4 2024, and down 197.11% on a QoQ basis from $727000.0 in Q3 2025.
Inhibrx Biosciences (INBX) Receivables (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 3 years of Receivables data on file, last reported at -$706000.0 in Q4 2025.
- On a quarterly basis, Receivables fell 1338.6% year-over-year to -$706000.0 in Q4 2025; TTM through Dec 2025 was -$706000.0, a 1338.6% decrease from a year earlier, with the FY2025 full-year figure at $200000.0, up 154.64% from the prior year.
- Receivables for Q4 2025 stood at -$706000.0, down from $727000.0 in the prior quarter.
- Over the last five years, Receivables for INBX reached as high as $1.1 million in Q2 2024 and fell as low as -$706000.0 in Q4 2025.
- Historically, Receivables has averaged $381714.3 across 3 years, with a median of $607000.0 in 2023.
- On a YoY basis, Receivables climbed as much as 857.29% in 2025 and fell as far as 1338.6% in 2025.
- Year by year, Receivables stood at $607000.0 in 2023, then tumbled by 90.61% to $57000.0 in 2024, then slumped by 1338.6% to -$706000.0 in 2025.
- Per Business Quant data, the three most recent Receivables figures were -$706000.0 in Q4 2025, $727000.0 in Q3 2025, and $967000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 4.97 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 938.02 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.13 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Inhibrx Biosciences | 1.32 Bn | 1.32 Bn | - | -706,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -706,000.00 |
| Sep 30, 2025 | 727,000.00 |
| Jun 30, 2025 | 967,000.00 |
| Dec 31, 2024 | 57,000.00 |
| Sep 30, 2024 | -96,000.00 |
| Jun 30, 2024 | 1.12 Mn |
| Dec 31, 2023 | 607,000.00 |